Brown University scientists published a Cell Reports study that decodes a molecular mechanism limiting glioblastoma response to existing therapies and identifies a targetable pathway to enhance treatment sensitivity. The team used integrated molecular and functional experiments to map intratumoral interactions that blunt therapeutic efficacy. Authors propose actionable combination strategies guided by the mechanism, and the paper includes preclinical validation suggesting improved tumor control when the pathway is co‑targeted. The findings may inform trial design for a disease with few durable treatment options and high unmet need.